Modulation of endothelial junctions as selective immunotherapy [ 2018 - ]

Research Grant

Researchers: Prof Jennifer Gamble (Principal investigator) ,  Prof Wolfgang Weninger

Brief description We have developed a new drug (CD5-2) that targets the junctions of endothelial cells, the cell that lines all vessels. CD5-2 reduces oedema in diseases such as diabetic retinopathy and tumours. Thus it has potential as a new therapeutic in chronic inflammatory diseases where leaky blood vessels are central to the pathology. This grant will provide fundamental understanding of how CD5-2 induces such profound effects to alter the levels of oedema and alter inflammatory cell infiltrates in tissues.

Funding Amount $911,387.00

Funding Scheme Project Grants

Notes Standard Project Grant